BAT5906

Asset

Neutralizes VEGF-A to inhibit abnormal blood vessel growth and vascular leakage in the retina.

Stage: Phase 1
Modality: Antibody
Target: VEGFA; 1
Indication: 1
Trial: 1
Developer

Indications

1

Age-related macular degeneration
Phase 1, Completed, NCT04151212, clinicaltrials.gov, 11 Oct 2026

In the full profile

Targets and what it contains1
Owner and partners1
Trials1
Evidence for its targets1
Competitors11
Signals1

Every asset’s record: target, stage, trials and the evidence behind it.